NCT00856687View on ClinicalTrials.gov

A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Asthma
Interventions
DRUG

PF-03893787

Oral, two doses 12 hours apart

DRUG

Placebo

Oral, two doses 12 hours apart

DRUG

Montelukast

Oral, two doses 12 hours apart

Trial Locations (1)

HA1 3UJ

Pfizer Investigational Site, Harrow

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY